Inflammatory bowel disease (IBD), including Crohn's disease (CD) and Ulcerative Colitis
(UC), are immune mediated conditions associated with progressive damage of the inflamed …

Therapy for inflammatory bowel disease (IBD) has changed, with several new agents being
evaluated. The era of anti-tumor necrosis factor (anti-TNF) antibody therapy saw remarkable …

Our growing understanding of the immunopathogenesis of inflammatory bowel disease
(IBD) has opened new avenues for developing targeted therapies. These advances in …

Background: The specific etiopathogenesis of inflammatory bowel disease (IBD) is still
unknown. Although the conventional anti-inflammatory or immunomodulatory drugs …

Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory condition of the
gastrointestinal tract. The two main forms of IBD are Crohn's disease and ulcerative colitis …

This review identifies possible pharmacological targets for inflammatory bowel disease (IBD)
within the IL‐23/IL‐17 axis. Specifically, there are several targets within the IL‐23/IL‐17 …

Background: Although TNF inhibitors revolutionized the therapy of inflammatory bowel
disease (IBD), we have been reaching a point where other therapies with different …

Inflammatory bowel disease (IBD) is a group of chronic disorders of the gastrointestinal tract
comprising Crohn's disease (CD) and ulcerative colitis (UC). Their etiologies are unknown …

Ulcerative colitis (UC) and Crohn's disease (CD) constitute the two major groups of
idiopathic disorders in inflammatory bowel disease (IBD). Environmental factors, genetic …

Inflammatory bowel disease (IBD) is a term used to represent a group of chronic, relapsing
inflammatory disorders of the gastrointestinal tract. Crohn's disease (CD) and ulcerative …